Clinical trial
LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
NCT02612194 is registered in ClinicalTrials.gov with Wake Forest University Health Sciences as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- LCI-GU-URO-CRI-001: A Phase II Study of Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
- Lead sponsor
- Wake Forest University Health Sciences
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 27, 2016
- Completion date
- November 21, 2019
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.